Ken Romeril, CEO Myeloma New Zealand Charitable Trust invites you to the Myeloma New Zealand Christmas Function 12 December, 5.00pm at BNZ Partners Centre, Level 10 Ricoh House, 1 Victoria St Wellington RSVP by Friday 7 December to contact@multiplemyeloma.org.nzContinue Reading

The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed or refractory multiple myeloma. Preliminary results from a Phase 1 trial (NCT03288493) suggest the candidate is safe and may have superior effectiveness compared with other CAR T-cell therapies. The RMAT designation...Continue Reading

There has been activity with chimeric antigen receptor (CAR) T cells in patients with relapsed diffuse large B-cell lymphoma (DLBCL), but Charalambos (Babis) Andreadis, MD, MSCE, says there are still several things to consider before choosing this treatment option for a patient. “It’s something that we’re very excited about, especially for patients with relapsed disease. We also...Continue Reading